Paper34901302
Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections.
Rebold N and 15 others. Open Forum Infect Dis, 2021. Cited by 27 papers, by iCite.
Cite this record
ConductScience Library. Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections. Papers, record 34901302. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34901302
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 AI121400 | NIAID NIH HHS | United States | R01AI121400 | PubMed |
Source NIH RePORTER
References22
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18929686 | Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. | J Biomed Inform | 2009 | https://conductscience.org/library/papers/18929686 | PubMed |
| 2 | 33191112 | The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study. | J Infect Chemother | 2021 | https://conductscience.org/library/papers/33191112 | PubMed |
| 3 | 27098166 | Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations. | Clin Infect Dis | 2016 | https://conductscience.org/library/papers/27098166 | PubMed |
| 4 | 29230684 | Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. | Drugs | 2018 | https://conductscience.org/library/papers/29230684 | PubMed |
| 5 | 31272373 | In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa. | BMC Microbiol | 2019 | https://conductscience.org/library/papers/31272373 | PubMed |
| 6 | 21793988 | Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. | Clin Microbiol Infect | 2012 | https://conductscience.org/library/papers/21793988 | PubMed |
| 7 | 31400759 | RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections. | Clin Infect Dis | 2020 | https://conductscience.org/library/papers/31400759 | PubMed |
| 8 | 28584849 | Carbapenem-Resistant Enterobacteriaceae Infections: Results From a Retrospective Series and Implications for the Design of Prospective Clinical Trials. | Open Forum Infect Dis | 2017 | https://conductscience.org/library/papers/28584849 | PubMed |
| 9 | 1244564 | Prediction of creatinine clearance from serum creatinine. | Nephron | 1976 | https://conductscience.org/library/papers/1244564 | PubMed |
| 10 | 26289307 | The β-Lactams Strike Back: Ceftazidime-Avibactam. | Pharmacotherapy | 2015 | https://conductscience.org/library/papers/26289307 | PubMed |
| 11 | 24957843 | Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia. | Antimicrob Agents Chemother | 2014 | https://conductscience.org/library/papers/24957843 | PubMed |
| 12 | 33830222 | Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). | Clin Infect Dis | 2021 | https://conductscience.org/library/papers/33830222 | PubMed |
| 13 | 26014931 | Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City. | Antimicrob Agents Chemother | 2015 | https://conductscience.org/library/papers/26014931 | PubMed |
| 14 | 7249508 | A method for estimating the probability of adverse drug reactions. | Clin Pharmacol Ther | 1981 | https://conductscience.org/library/papers/7249508 | PubMed |
| 15 | 27589330 | Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae. | Virulence | 2017 | https://conductscience.org/library/papers/27589330 | PubMed |
| 16 | 23696619 | Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. | J Antimicrob Chemother | 2013 | https://conductscience.org/library/papers/23696619 | PubMed |
| 17 | 29610205 | Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/29610205 | PubMed |
| 18 | 25070493 | New options of antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa. | Eur J Clin Microbiol Infect Dis | 2015 | https://conductscience.org/library/papers/25070493 | PubMed |
| 19 | 3928249 | APACHE II: a severity of disease classification system. | Crit Care Med | 1985 | https://conductscience.org/library/papers/3928249 | PubMed |
| 20 | 32785589 | A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study). | Clin Infect Dis | 2021 | https://conductscience.org/library/papers/32785589 | PubMed |
Cited by20
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42967154 | Responsible use of new antibiotics for critically ill patients suffering from infections due to carbapenem-resistant organisms-a narrative review for an enablement strategy. | JAC Antimicrob Resist | 2026 | https://conductscience.org/library/papers/42967154 | PubMed |
| 42016367 | Multicenter Evaluation of Ceftazidime/Avibactam in Pediatric Patients Across the United States: Real-World Insights into the Management of Drug-Resistant Gram-Negative Infections. | Open Forum Infect Dis | 2026 | https://conductscience.org/library/papers/42016367 | PubMed |
| 41867387 | Empiric Imipenem/Cilastatin/Relebactam for Febrile Neutropenia After Allogeneic Hematopoietic Stem Cell Transplantation: Two Case Reports. | J Blood Med | 2026 | https://conductscience.org/library/papers/41867387 | PubMed |
| 41384153 | Efficacy of Imipenem/Cilastatin/Relebactam in infections caused by Difficult-to-Treat Gram-Negative Bacteria: A Retrospective Analysis of Real-world data in Greece. | Infez Med | 2025 | https://conductscience.org/library/papers/41384153 | PubMed |
| 40583996 | Clinical efficacy, safety and pharmacokinetics of novel β-lactam/β-lactamase inhibitor combinations: a systematic review. | JAC Antimicrob Resist | 2025 | https://conductscience.org/library/papers/40583996 | PubMed |
| 40426594 | Breaking Through Resistance: A Comparative Review of New Beta-Lactamase Inhibitors (Avibactam, Vaborbactam, Relebactam) Against Multidrug-Resistant Superbugs. | Antibiotics (Basel) | 2025 | https://conductscience.org/library/papers/40426594 | PubMed |
| 39612160 | Real-World Experience of Imipenem-Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study). | Infect Dis Ther | 2025 | https://conductscience.org/library/papers/39612160 | PubMed |
| 39545060 | First case report of a vertebral osteomyelitis caused by carbapenem-resistant Enterobacter cloacae treated with imipenem/cilastatin/relebactam prolonged infusion then meropenem/vaborbactam in continuous infusion. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39545060 | PubMed |
| 39081883 | Real-world use of imipenem/cilastatin/relebactam for the treatment of KPC-producing Klebsiella pneumoniae complex and difficult-to-treat resistance (DTR) Pseudomonas aeruginosa infections: a single-center preliminary experience. | Front Microbiol | 2024 | https://conductscience.org/library/papers/39081883 | PubMed |
| 38792635 | Imipenem/Cilastatin/Relebactam for Complicated Infections: A Real-World Evidence. | Life (Basel) | 2024 | https://conductscience.org/library/papers/38792635 | PubMed |
| 38174096 | Global Resistance of Imipenem/Relebactam against Gram-Negative Bacilli: Systematic Review and Meta-Analysis. | Curr Ther Res Clin Exp | 2024 | https://conductscience.org/library/papers/38174096 | PubMed |
| 37383243 | Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis. | Open Forum Infect Dis | 2023 | https://conductscience.org/library/papers/37383243 | PubMed |
| 37107124 | Novel Antimicrobial Agents for Gram-Negative Pathogens. | Antibiotics (Basel) | 2023 | https://conductscience.org/library/papers/37107124 | PubMed |
| 36968951 | Impact of ompk36 genotype and KPC subtype on the in vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing K. pneumoniae clinical isolates. | JAC Antimicrob Resist | 2023 | https://conductscience.org/library/papers/36968951 | PubMed |
| 36544909 | Last resort beta-lactam antibiotics for treatment of New-Delhi Metallo-Beta-Lactamase producing Enterobacterales and other Difficult-to-Treat Resistance in Gram-negative bacteria: A real-life study. | Front Cell Infect Microbiol | 2022 | https://conductscience.org/library/papers/36544909 | PubMed |
| 36140042 | Epidemiology, Mechanisms of Resistance and Treatment Algorithm for Infections Due to Carbapenem-Resistant Gram-Negative Bacteria: An Expert Panel Opinion. | Antibiotics (Basel) | 2022 | https://conductscience.org/library/papers/36140042 | PubMed |
| 35892399 | Current and Potential Therapeutic Options for Infections Caused by Difficult-to-Treat and Pandrug Resistant Gram-Negative Bacteria in Critically Ill Patients. | Antibiotics (Basel) | 2022 | https://conductscience.org/library/papers/35892399 | PubMed |
| 35727059 | New Perspectives on Antimicrobial Agents: Imipenem-Relebactam. | Antimicrob Agents Chemother | 2022 | https://conductscience.org/library/papers/35727059 | PubMed |
| 35625223 | New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review. | Antibiotics (Basel) | 2022 | https://conductscience.org/library/papers/35625223 | PubMed |
| 35203879 | The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations. | Antibiotics (Basel) | 2022 | https://conductscience.org/library/papers/35203879 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| DPEP1 | 1800 | PubTator's text mining | https://conductscience.org/library/genes/1800 | NCBI Gene |
| INSR | 3643 | PubTator's text mining | https://conductscience.org/library/genes/3643 | NCBI Gene |
| OPRD1 | 4985 | PubTator's text mining | https://conductscience.org/library/genes/4985 | NCBI Gene |
| UBAC1 | 10422 | PubTator's text mining | https://conductscience.org/library/genes/10422 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34901302
GET https://conductscience.org/api/papers/v1/34901302/references?page=2